UCB to enter into an asset purchasing agreement with Exemed Pharmaceuticals for its Indian manufacturing facility

Tools

UCB to enter into an asset purchasing agreement with Exemed Pharmaceuticals for its Indian manufacturing facility

Brussels, November 23, 2012 - UCB announced today that Exemed Pharmaceuticals (Exemed), a fast-growing Indian company manufacturing and marketing high-quality active ingredients, will acquire UCB's Indian production facility in Vapi. The deal includes a multi-year supply agreement between UCB and Exemed as well as the transfer of UCB Vapi's ~80 members of staff to Exemed. The financial details regarding the deal are not disclosed.

The agreement is in line with UCB's strategy to focus on bringing new innovative drugs to patients and less on mass manufacturing for which UCB increasingly relies on a network of trusted partners. By choosing Exemed as its Indian partner, UCB is confidently transferring its production to a fast-growing manufacturing company that has the highest quality standards and growth ambitions for the site.

UCB's Vapi plant currently focuses on the production, packaging and distribution of some of UCB mature drugs mainly for the Indian market; it produces ~2% of total UCB volumes. Exemed Pharmaceuticals will continue with these activities while also planning to bring new business to the site.

The UCB-Exemed agreement and the long-term growth prospects it brings to the Vapi facility make the deal a win-win agreement for Exemed, UCB and UCB Vapi's employees. This transaction does not impact UCB's financial guidance for 2012


For further information

France Nivelle, Global Communications, UCB
T +32 2 559 9178, france.nivelle@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com

Antje Witte, Investor Relations UCB
T +32.2.559.9414, antje.witte@ucb.com

Notes to the editor

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).


UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.


There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.


Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.